Treatment of Liver Metastases in Patients with Neuroendocrine Tumors of Gastroesophageal and Pancreatic Origin

Table 2

Selected clinical trials of cytotoxic chemotherapy in advanced PNET**.

Regimen	No. of patients	Tumor response rates (%)	Median PFS month	Complete/partial response	Author (yr)
Prospective studies
Chlorozotocin	33	30	17	18	Moertel et al. [19] (1992)
STZ + 5FU	33	45	14	16.8
STZ + DOX	36	69	18	26.4
DTIC	50	34	NR	19.3	Ramanathan et al. [20] (2001)
Retrospective studies
STZ + 5FU + DOX	84	39	18	37	Kouvaraki et al. [21] (2004)
TMZ various  chemotherapy	53	34	13.6	35.3	Kulke et al. [22] (2009)
TMZ + Capecitabine	30	70	18	NR	Strosberg et al. [23] (2010)

**Several of the early studies often assessed tumor response and PFS by clinical and not imaging parameters.
PFS: progression-free survival, STZ: streptozocin, 5FU: 5-flurouracil, DOX: doxorubicin, DTIC: dacarbazine, TMZ: temozolomide, NR: not reported.